Stay updated with breaking news from Sight Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sight Sciences, Inc. (SGHT) Tuesday announced the positive results in its ROMEO multi-center evaluation of the severity of glaucoma, the intraocular pressure or IOP, and medication outcomes for patients treated with the OMNI Surgical System.
Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) CFO Alison Bauerlein sold 13,066 shares of the firm’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $5.42, for a total value of $70,817.72. Following the transaction, the chief financial officer now owns 413,182 shares of the company’s […]
Operator: Good day, and thank you for standing by. Welcome to the Sight Sciences First Quarter 2024 Earnings Results Conference Call. At this time, all participants are in a listen-only mode.
Piper Sandler restated their neutral rating on shares of Sight Sciences (NASDAQ:SGHT – Free Report) in a research report released on Friday, Benzinga reports. The brokerage currently has a $6.00 target price on the stock, up from their previous target price of $5.00. Separately, Needham & Company LLC reaffirmed a hold rating on shares of […]
Shares of Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) have earned an average rating of “Hold” from the seven brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has assigned a buy recommendation to […]